It should also be acknowledged that, due to small sample size (<30), other relevant comorbidities/medication use that could have had an impact on treatment selection, such as autoimmune disorders, dementia/cognitive dysfunction, and diabetics with subcutaneous insulin, could not be adjusted in the model. This evidence concerns the gene INS and dementia.